Tango Therapeutics (TNGX) stock, explained like you're 5

Is Tango Therapeutics a small, medium or large cap company?

No. Tango Therapeutics is a mid cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 4 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Tango Therapeutics makes money

• Selling medicines, medical devices or healthcare services.
• Insurance premiums or hospital and clinic fees.
• Research and licensing deals.

What moves TNGX stock

• Results from clinical trials and approvals from regulators.
• Drug prices, insurance rules and government policy.
• Patents running out and new competing treatments.

In the news lately

• Updated Trial Data Might Change The Case For Investing In Tango Therapeutics Stock (TNGX) (Simply Wall Street)
• Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026 (Yahoo Finance)
• JPMorgan reiterates Tango Therapeutics stock rating ahead of ESMO data (Investing.com)
• Tango Therapeutics to Present Updated Phase 1/2 Data for Vopimetostat Combinations in MTAP Deleted RAS Mutant Pancreatic and Lung Cancers at ESMO 2026 (Quiver Quantitative)
• Tango Therapeutics (TNGX) executive exercises options at $5.20 and sells 27,000 shares (Stock Titan)

Key terms to know before you follow TNGX

• Market cap
• P/E ratio
• EPS (earnings per share)
• Earnings report
• Volatility